The data that Gilead Sciences subsidiary Kite and Arcellx presented at the American Society of Hematology meeting for anitocabtagene autoleucel (anito-cel) were positive, but the question that remains is whether the apparent safety and tolerability advantage will be sufficient to give the BCMA-directed CAR-T cell therapy a competitive edge over the two players already on the market.
The companies presented data from the Phase II iMMagine-1 study at the ASH annual meeting n San Diego on 9 December, while also laying out plans for a confirmatory Phase...
Key Takeaways
- Gilead's Kite subsidiary and Arcellx presented positive data at ASH from the Phase II iMMagine-1 trial of anitocabtagene autoleucel, showing a 97% ORR and a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?